Niagen Bioscience Inc
Research Niagen Bioscience Inc (NAGE) on Bullrun: market cap USD 258.03M, P/E 17.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNAGE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 258.03M
- P/E17.4
- Financial periodQ2 2026
- RevenueUSD 29.79M
- Net incomeUSD 963.00K
- Free cash flowUSD 2.68M
- Gross margin64.8%
Valuation Snapshot
latest market cap is USD 258.03M; P/E is 17.4.
Peer valuation comparison
Latest P/E is 17.38x versus a Healthcare sector median of 24.46x (28.9% below).
Latest P/E is 17.38x versus a United States median of 24.87x (30.1% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 129.42M | USD 17.38M | USD 13.21M | 64.3% | 0.2 | USD 64.79M | USD 2.82M | USD 76.53M |
| FY2024 | USD 99.60M | USD 8.55M | USD 11.95M | 61.8% | 0.11 | USD 44.50M | USD 2.65M | USD 46.09M |
| FY2023 | USD 83.57M | -USD 4.94M | n/a | 60.8% | -0.07 | USD 27.20M | USD 3.28M | USD 28.46M |
| FY2022 | USD 72.05M | -USD 16.54M | n/a | 59.4% | -0.24 | USD 20.30M | n/a | USD 28.67M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 258.03M | 17.4 | n/a | n/a |
| 2025 | 2025-12-31 | USD 506.98M | 31.8 | n/a | n/a |
| 2024 | 2024-12-31 | USD 410.62M | 48.3 | n/a | n/a |
| 2023 | 2023-12-29 | USD 107.43M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 125.11M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 254.79M | n/a | n/a | n/a |
About Niagen Bioscience Inc
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Niagen Bioscience Inc's market cap?
Niagen Bioscience Inc's market capitalization is USD 258.03M.
What is Niagen Bioscience Inc's P/E ratio?
Niagen Bioscience Inc's price-to-earnings (P/E) ratio is 17.4.
What does Niagen Bioscience Inc do?
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments.